Posted by john on July 31st, 2006 — in Zyrtec Top News
Ohio residents without prescription-drug insurance aren’t going to get a discount at the pharmacy any time soon.
Prices for prescription drugs have risen at three times the rate of inflation since 1994, and uninsured Ohioans are paying those prices.
Uninsured Ohioans pay twice as much as federal workers for the 10 most common prescription medications taken by […]
No Comments »
Posted by john on July 30th, 2006 — in Zyrtec Top News
Protopic, also known as tacrolimus 0.1 percent ointment, suppresses the signs and symptoms of skin allergy resulting in contact dermatitis among individuals who are sensitive to nickel and who continue to be exposed to this metal, a new study shows.
The investigators used nickel to create an experimental model of chronic allergic contact dermatitis. “Theoretically, since […]
No Comments »
Posted by john on July 28th, 2006 — in Zyrtec Top News
Belgian pharmaceutical group UCB SA posted a forecast beating 44 pct jump in first half net profit, including capital gains, to 237 mln eur from 165 mln a year earlier.
Analysts had forecast a more modest rise to 184-197 mln eur.
Sales climbed to 1.322 bln eur from 1.18 bln a year ago, again outpacing estimates of […]
No Comments »
Posted by john on July 24th, 2006 — in Zyrtec Top News
Belgian pharmaceutical group UCB SA will post first-half results before the market opening on Thursday showing a strong increase in sales and net profit, according to analysts polled by AFX News.
Net profit, including capital gains, is seen at 184-197 mln eur, up from 165 mln eur last year on sales of between 1.252-1.300 bln eur […]
No Comments »
Posted by john on July 20th, 2006 — in Zyrtec Top News
BRUSSELS (AFX) - Pfizer, Inc. said its second quarter US sales of Belgian pharmaceutical company UCB SA’s antihistamine drug Zyrtec rose to 377 mln usd from 355 mln a year earlier.
Zyrtec, which is licensed to Pfizer in the US, goes off patent in the US at the end of 2007.
It is part of Pfizer’s consumer […]
No Comments »
Posted by john on July 17th, 2006 — in Zyrtec Top News
There have been increasing concerns over whether corporations can sustain the double-digit profit gains, given the dark clouds hanging over the tech space and profit warning from diversified technology company 3M Co. Second quarter earnings season got off to a slow start last week, and the performance seen thus far in the season and the […]
No Comments »
Posted by john on July 15th, 2006 — in Zyrtec Top News
ASTHMA, eczema and hay fever could be cured within five years if pioneering work by Manchester experts is successful.
Researchers at Manchester University are developing drugs that stop allergens - the substances that cause allergies - from entering the body in the first place.
Prof David Garrod, from the department of Life Sciences, believes new products could […]
No Comments »
Posted by john on July 11th, 2006 — in Zyrtec Top News
When I first moved to Delaware, people warned me of our state’s propensity to cause sinus and allergy woes where none existed before. Being blessed with clear nasal passages for most of my life, I considered myself immune to such dire warnings.
More than four years later, I find that a subtle pressure behind my eyes […]
No Comments »
Posted by john on July 7th, 2006 — in Zyrtec Top News
Mice infected with the agent of scrapie — a brain-wasting disease of sheep — suffered heart damage and had high levels of the scrapie agent in their heart about two years after they were infected in the brain, a new U.S. study finds.
The finding suggests that heart infection may be a previously unrecognized aspect of […]
No Comments »
Posted by john on July 5th, 2006 — in Zyrtec Top News
But Pfizer, which has been in Morris Plains since 1999, would not be leaving.
Under the sale agreement, Pfizer would share its 175-acre property with J&J, keeping the research and development arm and prescription medication wing on the west side of Route 53, with J&J taking the eastern portion, much of which is still under construction […]
No Comments »